96 related articles for article (PubMed ID: 12645906)
1. ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study.
Murakami H; Tamura T; Yamada Y; Yamamoto N; Ueda Y; Shimoyama T; Saijo N
Eur J Cancer; 2002 Dec; 38 Suppl 8():S1-5. PubMed ID: 12645906
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.
Twelves C; Reck M; Anthoney A; Gatzemeier U; Kaye S
Cancer Chemother Pharmacol; 2003 Oct; 52(4):277-81. PubMed ID: 12827291
[TBL] [Abstract][Full Text] [Related]
3. ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies.
Douillard JY; Schiller J
Eur J Cancer; 2002 Dec; 38 Suppl 8():S25-31. PubMed ID: 12645909
[TBL] [Abstract][Full Text] [Related]
4. Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval.
Gore ME; Atkinson RJ; Thomas H; Cure H; Rischin D; Beale P; Bougnoux P; Dirix L; Smit WM
Eur J Cancer; 2002 Dec; 38 Suppl 8():S7-12. PubMed ID: 12645907
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.
Akshintala S; Marcus L; Warren KE; Murphy RF; Sissung TM; Srivastava A; Goodspeed WJ; Goodwin A; Brewer CC; Zalewski C; King KA; Kim A; Figg WD; Widemann BC
Pediatr Blood Cancer; 2015 Apr; 62(4):603-10. PubMed ID: 25556988
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.
Gore ME; Atkinson RJ; Thomas H; Cure H; Rischin D; Beale P; Bougnoux P; Dirix L; Smit WM
Eur J Cancer; 2002 Dec; 38(18):2416-20. PubMed ID: 12460786
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ZD0473 as second-line therapy in mesothelioma.
Giaccone G; O'Brien ME; Byrne MJ; Bard M; Kaukel E; Smit B
Eur J Cancer; 2002 Dec; 38 Suppl 8():S19-24. PubMed ID: 12647701
[TBL] [Abstract][Full Text] [Related]
8. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of oral JM216 given twice daily.
Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
[TBL] [Abstract][Full Text] [Related]
12. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Flaherty KT; Stevenson JP; Redlinger M; Algazy KM; Giatonio B; O'Dwyer PJ
Cancer Chemother Pharmacol; 2004 May; 53(5):404-8. PubMed ID: 15129676
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
16. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
17. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
[TBL] [Abstract][Full Text] [Related]
18. ZD0473 treatment in lung cancer: an overview of the clinical trial results.
Treat J; Schiller J; Quoix E; Mauer A; Edelman M; Modiano M; Bonomi P; Ramlau R; Lemarie E
Eur J Cancer; 2002 Dec; 38 Suppl 8():S13-8. PubMed ID: 12645908
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
20. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Gerrits CJ; Burris H; Schellens JH; Planting AS; van den Burg ME; Rodriguez GI; van Beurden V; Loos WJ; Hudson I; Fields S; Verweij J; von Hoff DD
Eur J Cancer; 1998 Jun; 34(7):1030-5. PubMed ID: 9849451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
